Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2013
At a glance
- Drugs Afatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 08 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 19 Jan 2013 Planned number of patients changed from 29 to 57 as reported by European Clinical Trials Database.